Quality of life, Body image, and psychiatric implications in patients with urn trauma: preliminary study of the Italian version of Burn Specific Health Scale-brief

Burn patients may suffer both physical and psychopatological consequences and their quality of life and the presence of psychopathological symptoms should be evacuate. The Burn Specific Health Scale-Brief (BSHS-B) is a tried and test-instrument for assessing burn patients’ quality of life. The aim of this study is to propose the Italian translation of BSHS-B and presents the preliminary results of an exploratory study. The Italian version of BSHS-B was administered to a sample group of 50 burn victims. Reliability was verified by Cronbach’s alpha, and construct validity was evaluated through correlation with the Short Form 36 Health Survey Questionnaire (SF-36) and the Self-report Symptom I…

ASSOCIATION BETWEEN COPING STRATEGIES AND PSYCHOLOGICAL ADJUSTMENT AFTER SMALL BURN INJURIES. A CROSS-SECTIONAL STUDY

Objective: This study aimed at describing the coping strategies used by patients of small burns (<= 20% body surface area) at the early stage of rehabilitation process and to analyze the effect of coping strategies and body image dissatisfaction on psychiatric symptoms and quality of life.Method: Sixty-nine patients firstly admitted to an out-patient burn unit were involved in the study. Coping response to burn trauma was investigated using the Brief-COPE, while the Short-Form 36 Health Survey, the Self-report Clinical Inventory, and the Body Uneasiness Test were used respectively to assess post-burn quality of life, psychiatric symptoms, and body image dissatisfaction.Results: Avoidant …

Qualità di Vita, immagine del corpo e complicanze psichiatriche in pazienti con trauma da ustione

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomized, double blind, placebo controlled, phase III study.

Objective To assess the efficacy of recombinant human erythropoietin (rhEPO) in amyotrophic lateral sclerosis (ALS). Methods Patients with probable laboratory-supported, probable or definite ALS were enrolled by 25 Italian centres and randomly assigned (1:1) to receive intravenous rhEPO 40 000 IU or placebo fortnightly as add-on treatment to riluzole 100 mg daily for 12 months. The primary composite outcome was survival, tracheotomy or >23 h non-invasive ventilation (NIV). Secondary outcomes were ALSFRS-R, slow vital capacity (sVC) and quality of life (ALSAQ-40) decline. Tolerability was evaluated analysing adverse events (AEs) causing withdrawal. The randomisation sequence was computer-…